Acquired hemophilia A in women postpartum is diagnosed by a prolonged activated partial thromboplastin time (APTT), low plasma levels of coagulant factor VIII, and the detection of an inhibitor against factor VIII in the Bethesda assay. Effective treatment of bleeding symptoms should be based upon the clinical situation and depends on the inhibitor characteristics against human and porcine factor VIII. Immu-nosuppression usually does not significantly affect the disappearance of the factor VIII inhibitor antibody. The natural history of acquired hemophilia postpartum is independent of immunosuppressive treatment and featured by spontaneous disappearance of the inhibitor against factor VIII in the majority of cases.
lands Summary: Acquired hemophilia A in women postpartum is diagnosed by a prolonged activated partial thromboplastin time (APTT), low plasma levels of coagulant factor VIII, and the detection of an inhibitor against factor VIII in the Bethesda assay. Effective treatment of bleeding symptoms should be based upon the clinical situation and depends on the inhibitor characteristics against human and porcine factor VIII. Immu-nosuppression usually does not significantly affect the disappearance of the factor VIII inhibitor antibody. The natural history of acquired hemophilia postpartum is independent of immunosuppressive treatment and featured by spontaneous disappearance of the inhibitor against factor VIII in the majority of cases.
The occurrence of inhibitors with antibody activity, selectively directed against the antihemophilic factor VIII, may complicate classical hemophilia A or develop in patients with immunological diseases, eg, rheumatoid arthritis, systemic lupus erythematosus, penicillin allergy, other auto-immune disorders, dermatological and respiratory diseases, and malignancies including lymphoproliferative disorders and solid tumors (1) (2) (3) . In a review of 215 nonhemophiliac patients who developed inhibitors against factor VIII, an underlying disorder was detectable in 47% of patients; in 7% of patients, an underlying disorder occurred in women postpartum; and in 46% of patients, no underlying disorders were identified (3) .
The presence of a factor VIII inhibitor may lead to life-threatening hemorrhages. The clinical suspicion of acquired hemophilia A usually arises in elderly patients and in women postpartum with no previous bleeding history, who develop soft tissue bleeding and bruising, hemarthrosis, or gastrointestinal bleeding (3, 4) . Laboratory investigations characteristically show a prolonged activated partial thromboplastin time (APTT), no correction of the prolonged APTT to normal in a mixture of patient and normal plasma, reduced levels of factor VIII coagulant activity, and an inhibitor against factor VIII in the Bethesda assay (5) .
The occurrence of an acquired factor VIII inhibitor related to pregnancy is rare. In 1978, we described our first case and reviewed 27 cases from the literature (4) ( Table 1 ). Since then, 12 well documented cases have been reported (6) (7) (8) (9) (10) (11) (12) (13) (14) (Tables 1,2 ). The presenting symptoms in these 40 cases of acquired hemophilia A postpartum are rather dissimilar to those in severe congenital hemophilia A in that bruises, ecchymoses, and bleedings in the soft tissues are remarkably frequent (Table 1) . Joint bleedings usually occur infrequently during followup in nearly half of the reported cases. As shown in table l, the appearance of a hemorrhagic diathesis during pregnancy has been observed in only one patient: it occurred after an abortion in one case, immediately after delivery in eight cases, after a free time interval of a few weeks in four patients, of 1 to 4 months in 18 patients, and 4 to 12 months in nine patients.
The etiology of acquired hemophilia A in women postpartum is unknown (4, 6) . The inhibitor had developed in primi-and multi-parae after the birth of boys as well as girls. It is thought that the pregnant mother may be sensitized by fetal factor VIII (6) . As in Rhesus sensitization, one would expect such an alloantibody to reappear after some of the subsequent pregnancies. However, in a study following pregnancy in 10 cases with previous hemophilia A, the postpartum state was reported to cause no reappearance of the inhibitor (4,6,9, 14) ( Table 2 ). Voke (15) observed spontaneous disappearance of the inhibitor during a subsequent pregnancy. In two cases, the inhibitor remained present during and after a following pregnancy and could be detected in the blood of the second child ( 10, 16) . The duration of hemophilia A disease postpartum may vary from a few months to several years (Table 1 ). Two patients died of respiratory obstruction from a sublingual hematoma, and another died after massive retroperitoneal hemorrhage. A Human antibodies that inactivate factor VIII precoagulant factor are heterogeneous in their kinetic properties (17) . Type I antibodies are usually very potent, have second order inactivation kinetics, and completely inhibit factor VIII coagulant activity both in vitro and in vivo. These properties of type I factor VIII inhibitors correspond with both no detectable factor VIII in vivo and no recovery of very high dosages of human factor VIII concentrate substitution. Type II factor VIII antibodies have more complex kinetics and do not completely inactivate factor VIII, even when tested undiluted. These properties of type II factor VIII inhibitors correspond with both the observation of a significant, but reduced, recovery of high dosages of human factor VIII substitution and the in vivo finding in some patients that there is detectable factor VIII, even though there is a significant titer (4, 14, 17) .
Success or failure in the treatment of bleeding symptoms with human factor VIII concentrate in acquired hemophilia A postpartum depends on the quantitative and qualitative characteristics of the inhibitor (17) . The potency of the factor VIII inhibitor in acquired hemophilia A postpartum is rather low in the majority of cases, and high in only a minority (4, 14, 18) . The median inhibitor level in 24 patients with acquired hemophilia A postpartum was rather low-20 Bethesda Units (BU) (18) . In vitro inactivation of low titer factor VIII inhibitor in acquired hemophilia A postpartum usually shows an antibody of nonlinear type II factor VIII inactivation (4, 14) . These low titer, type II factor VIII inhibitors also show an incomplete factor VIII inactivation pattern in vivo after transfusion of factor VIII concentrate (4, 14) . Therefore, it does not seem to be necessary to neutralize the inhibitor completely to obtain a factor VIII level of sufficient hemostatic potency (4, 14) . Moreover, factor VIII substitution in acquired hemophilia is not followed by an anamnestic response in inhibitor titer. High dose intravenous immunoglobulin in acquired hemophilia A postpartum occasionally has been described to be effective in reducing the type II inhibitor titer associated with a transient increase of measurable factor VIII levels for 1 to 2 weeks (14) .
High titer factor VIII inhibitors are usually type I. In contrast to type II inhibitors, factor VIII inhibitors-type I are very potent, usually induce severe bleeding symptoms, persist for a long time or even do not disappear, and completely inhibit the patient's and transfused human factor VIII, even after substitution of very high dosages (14, 17) . Fortunately, both type I and II factor VIIIacquired inhibitors against factor VIII in elderly patients and women postpartum do not crossreact with porcine factor VIII (HyateR-C) in a significant number of cases (19, 20) . In the instance of no crossreactivity, porcine factor VIII substitution therapy is effective and, therefore, the treatment of choice to arrest acute and persistent bleeding episodes. In case of crossreactivity of the factor VIII inhibitor with porcine factor VIII with potencies in excess of 10 BU, treatment of severe bleedings with FEIBA, Autoplex, or recombinant FVIIa (NovoSevenR) is recommended (20) .
The final outcome of postpartum inhibitors is favorable, with a probability of disappearance of the inhibitor in the majority of cases (4, 18) . From our report in 1978 (4) and the present study (Table 1) , the inhibitor disappeared spontaneously in 25 out of 40 cases. No remission was observed in 11 cases after a follow-up period of a few to 108 months (Tables 1,2) or even 24 years in one exceptional case (14) . Treatment with prednisone was found to be ineffective in acquired hemophilia postpartum (4, 14, 18) (Table 1 ). Our first case (4) showed gradual disappearance of factor VIII inhibitor both during and after azathioprine treatment, but this may have coincided with the spontaneous disappearance of the inhibitor after 10 months. In a recent analysis of 51 patients with postpartum factor VIII inhibitor, the time to disappearance of the inhibitor was 8 months in 18 patients who were treated with immunosuppressives; 12 months in 23 patients who were treated with steroids; and 16 months in 10 patients who were given neither steroids nor immunosuppressive treatment ( 18) . This study demonstrates that immunosuppression in acquired hemophilia A postpartum does not induce the disappearance of the factor VIII inhibitor (complete remission), but may slightly reduce the time to complete remission after discontinuation of the immunosuppressive treatment. This conclusion has to be regarded with very great caution, for the decision as to whether or not to treat such patients accordingly (14) . In our experience, cyclophosphamide in one case and a combination of prednisone plus cyclophophamide in another case of acquired hemophilia A TABLE 2-(Continued) postpartum did not reduce the inhibitor titer; however, spontaneous and gradual disappearance of the inhibitor was not observed until up to 6 months and 1 year, respectively, after discontinuation of immunosuppression (14) . In contrast, in a group of elderly patients, both women and men, who were suffering from acquired hemophilia A, immunosuppressive treatment with prednisone, cyclophosphamide, or prednisone, followed by cyclophophamide, indeed did induce the disappearance of autoantibodies against factor VIII in the majority of these patients (21) .
CONCLUSIONS
In contrast to the effectiveness of immunosuppressive therapy in the majority of elderly patients with acquired hemophilia A (21), there is no convincing evidence that immunosuppression is effective in acquired hemophilia A in women postpartum (4, 14, 18) . Fortunately, the natural history of the hemophilic disease postpartum is characterized by a spontaneous disappearance of the factor VIII inhibitor in the majority of the cases after a mean period of 30 months (4, 14, 18) . In acquired hemophilia A postpartum, the factor VIII inhibitor is usually of type II, with potency varying from weak to moderate (4, 14) . In those cases, the inactivation of transfused factor VIII by a type II inhibitor is not complete (14) . Therefore, treatment of bleeding episodes with high dose human or recombinant factor VIII concentrate is feasible and should not be reserved for life-threatening hemorrhages only. The effect of high dose intravenous immunoglobulin should be tested, because it may transiently reduce the inhibitor titer through a reappearance and increase of an in vivo factor VIII level of sufficient hemostatic potency (14) . In the case of no crossreactivity of factor VIII inhibitor type I and II with porcine factor VIII, HyateR-C is the treatment of choice to arrest minor, severe, or lifethreatening bleeding episodes in acquired hemophilia A that occurs in women postpartum or in elderly patients (19) (20) (21) (22) . Acquired hemophilia A, with high titer type I factor VIII inhibitors against human factor VIII, has a high risk of severe bleeding complications, which should be treated with recombinant factor VII~ (NovoSevenR) or FeibaR (20, 22) .
